ArticleJCEM case reports2026
Pheochromocytoma unmasked by rapid deterioration of previously stable type 2 diabetes.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 46-year-old man with a 15-year history of type 2 diabetes had maintained hemoglobin A1c (HbA1c) around 6.5% (SI: 48 mmol/mol) (reference range, 4.7%-6.2% [28-44 mmol/mol]) for approximately 12 years on saxagliptin monotherapy, but glycemic control worsened over 1 year despite additional ipragliflozin and metformin. Abdominal computed tomography (CT), performed after health-screening urine dipstick protein positivity, detected a left adrenal mass. He had tachycardia and weight loss but no palpitations, headache, pallor, or diaphoresis. Biochemical tests showed marked catecholamine excess and elevated 24-hour urinary metanephrines, and iodine-123 metaiodobenzylguanidine (123I-MIBG) scintigraphy showed concordant uptake. Before surgery, fasting C-peptide was 0.64 ng/mL (SI: 0.21 nmol/L) (reference range, 0.80-2.50 ng/mL [SI: 0.26-0.83 nmol/L]), C-peptide index was 0.51, and homeostasis model assessment of beta-cell function (HOMA-beta) was 11.0. After alpha blockade and volume expansion, laparoscopic left adrenalectomy confirmed pheochromocytoma. Antihypertensive and glucose-lowering medications were discontinued postoperatively, and glycemic control remained stable without antidiabetic medication at 6 months. This case highlights pheochromocytoma as a reversible endocrine cause of rapid worsening of previously stable type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.